FDA Clearance Tracker · P960009-S391
Activa, Percept and SenSight Deep Brain Stimulation Therapy System
Last checked: Nov 20, 2026Latest source record: May 25, 2021 (this decision)Source: openFDAMethods & limitations
Decided
May 25, 2021
Approved
Time to decision
179 days
Received Nov 27, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P960009-S391
- Device name
- Activa, Percept and SenSight Deep Brain Stimulation Therapy System
- Applicant
- Medtronic, Inc.
- Applicant location
- Minneapolis, MN
- Received
- Nov 27, 2020
- Decided
- May 25, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P960009
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the SenSight Directional Lead System and updates to Model A610 DBS Clinician Programmer Application (CPA) Software to version 3.0.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.